For the risk stratification of indeterminate thyroid nodules

Blog
Contact Us
Payment
Physician Portal

Please visit us at ENDOExpo 2024 (Booth 626)

Visit Us at the ATA 2026 Annual Meeting—Booth #48

View Observational Study

Go Now

ThyGeNEXT+ThyraMIRv2

View of thyroid case (Hürthle cell)

Oncocytic (formerly Hürthle Cell) Thyroid Nodules: Risk-Stratification with ThyGeNEXT + ThyraMIRv2

By

Oncocytic thyroid nodules, formerly known as Hürthle cell nodules, can present a diagnostic challenge. These lesions are composed of cells with abundant eosinophilic cytoplasm caused by mitochondrial accumulation.1 Although malignant oncocytic tumors are relatively rare, they are clinically significant due to their aggressive behavior and high risk of recurrence and distant metastasis.1-3 Oncocytic thyroid carcinoma […]

Oncocytic (formerly Hürthle Cell) Thyroid Nodules: Risk-Stratification with ThyGeNEXT + ThyraMIRv2 Read More »

ThyraMIRv2 Provides Insight Into Signaling Pathway Genes

By

ThyGeNEXT®+ThyraMIR®v2 is a unique combination testing platform that utilizes an assessment of the most common mutations associated with all types of thyroid carcinoma and microRNA signatures that provide deep insight into the epigenetic regulation of cancer signaling pathways. The assessment of microRNAs with ThyraMIRv2 enables the testing platform to help rule in malignancy, even in

ThyraMIRv2 Provides Insight Into Signaling Pathway Genes Read More »

Indeterminate Thyroid Nodules: Mutations and Risk Stratification

By

Within every thyroid nodule lies a genetic story. Molecular testing helps decode that story by analyzing mutations that can help identify whether the nodule is benign or malignant, and can potentially reduce unnecessary surgeries.  Molecular diagnostic testing platforms, like ThyGeNEXT®+ThyraMIR®v2, provide analyses that include the identification of mutations that help to rule in or diagnose

Indeterminate Thyroid Nodules: Mutations and Risk Stratification Read More »

Observational Study Performance Aligns with Clinical Validation Study

By

A real-world observational study provided data supporting the high performance of the ThyGeNEXT®+ThyraMIR®v2 combination testing platform for evaluating cytologically indeterminate thyroid nodules.1 The performance metrics aligned with the most recent clinical validation study, helping reinforce the utility of this combination approach in everyday clinical settings.

Observational Study Performance Aligns with Clinical Validation Study Read More »